https://ioannis-mouratidis.github.io/tags/Startup/StartupHugo Blox Builder (https://hugoblox.com)en-usSat, 01 Jan 2022 00:00:00 +0000https://ioannis-mouratidis.github.io/media/icon_hu_899445b689d8f445.pnghttps://ioannis-mouratidis.github.io/tags/Startup/https://ioannis-mouratidis.github.io/projects/neomer-diagnostics/Sat, 01 Jan 2022 00:00:00 +0000https://ioannis-mouratidis.github.io/projects/neomer-diagnostics/<h2 id="overview">Overview</h2> <p>Co-founded Neomer Diagnostics in 2022 as Chief Technical Officer to translate patented nullomer research into a clinical cancer detection platform. The company developed machine learning pipelines for detecting cancer from liquid biopsies.</p> <h2 id="role--achievements">Role &amp; Achievements</h2> <p>As CTO, I:</p> <ul> <li>Developed ML pipeline in Bash, Julia, Python, and Slurm for cancer detection from liquid biopsies</li> <li>Achieved AUC ranging from 0.89 to 0.94 in lung and ovarian cancers</li> <li>Established regulatory roadmap for clinical validation and FDA approval</li> <li>Secured $850K in translational research funding</li> <li>Led technical team and coordinated with clinical partners</li> </ul> <h2 id="technology">Technology</h2> <p>The platform leveraged sequences absent from the human genome (nullomers) as biomarkers for cancer detection. Machine learning models were trained on cell-free DNA and RNA data from liquid biopsies to distinguish cancer patients from healthy controls.</p> <h2 id="clinical-applications">Clinical Applications</h2> <ul> <li>Early cancer detection</li> <li>Cancer screening in high-risk populations</li> <li>Monitoring treatment response</li> <li>Detecting minimal residual disease</li> </ul> <h2 id="funding--recognition">Funding &amp; Recognition</h2> <ul> <li>Secured $850K in translational research funding</li> <li>Patent portfolio covering nullomer-based diagnostics</li> <li>Partnerships with clinical institutions</li> </ul> <h2 id="period">Period</h2> <p>January 2022 - May 2023</p>